Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$12.86 USD
+1.88 (17.12%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $12.85 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 81 - 100 ( 136 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Revised REMS Proposal For Sparsentan in IgAN Submitted; New PDUFA Date February 17, 2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With ASN/Kidney Week Approaching, TVTX Focuses on 2/17/23 PDUFA
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year Of The Kidney Extended To 2023 As Sparsentan PDUFA Shifts Out on REMS Add
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sparsentan PDUFA Delayed; Reducing PT to $36 on More Gradual Uptake and Potential Liver Tox Risk
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Commercial Biotech Preview: Regulatory Catalysts Likely The Main Event
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sparsentan Accepted for Review by EMA in IgAN; EU Approval Expected in 2H23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: NDA Filing in FSGS Delayed to 2H23; IgAN Remains On Track; Pegtibatinase Granted BTD; Reduce PT to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year of the Kidney: ERA-EDTA Just the Start, Raising KDNY Target
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Recap: November 17 PDUFA Date Paves a Path to 4Q22 Launch of Sparsentan in IgAN; Raise PT to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Regulatory Hurdle Cleared - Sparsentan IgAN Filing Accepted
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Uneventful 1Q22 Update, But Many Regulatory Catalysts On Horizon
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vive La France! [KDNY] Atrasentan Data Among ERA-EDTA Abstract Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Commercial Biotech Preview: Let''s Get It Over With
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year of the Kidney: A Deep Dive Primer On Glomerular Disorders
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sparsentan IgAN Submission Arrives on Time ? On to the Next One
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L